The Hospital Universitario de Fuenlabrada is seeking suppliers for the provision of a specific radiopharmaceutical, Lutathera® (with active ingredient [177-LU]-DOTA0-TYR3-OCTREOTATO), in a concentration of 370 MBq/mL for infusion. This contract is valued at approximately €279,936 and is part of the
Contract awarded. Originally published 9 months ago.
No single supplier dominates the field.
In healthcare medical, PUBLIC ENTITY UNIVERSITY HOSPITAL OF FUENLABRA has awarded 5 contracts to 5 suppliers.
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract involves the supply of exclusive Cyramza medications from Lilly for the Fuenlabrada University Hospital. The total value of the contract is €106,375. Suppliers are invited to provide these specific medications, which are essential for patient care in the health sector. The awarded supp
The Hospital Universitario de Fuenlabrada is seeking suppliers for laboratory materials, including reagents, controls, calibrators, and specific consumables. Additionally, suppliers must provide the necessary equipment for conducting autoimmunity determinations in the hospital's laboratory. This con
The Hospital Universitario de Fuenlabrada is seeking suppliers for the provision of implantable, radiopaque artificial urinary sphincters specifically designed for male patients. This contract is valued at €170,000 and is part of the health sector. The awarded supplier for this contract is Productos
NHS Scotland is seeking suppliers of generic and biosimilar cancer medicines to improve patient access and optimize healthcare costs.
Royal Borough of Greenwich is commissioning a School Health and Wellbeing Service to deliver preventative health and early intervention support for children and young people aged 5-19 years across the borough, with contract commencement in April 2027.
Suffolk County Council is testing market interest for postal delivery of nicotine replacement therapy and smoking cessation medications to improve accessibility for local residents.
PSD Scotland is engaging with the market to explore delivery solutions for a national Targeted Lung Cancer Screening Programme for smokers aged 55-74 in Scotland.
